Opinion|Videos|September 16, 2024
Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis
Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?
Advertisement
Related to this article
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
6 Nephrology Headlines You Missed in September 2026
5